These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15639687)

  • 21. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.
    Wang SZ; Hu JT; Zhang C; Zhou W; Chen XF; Jiang LY; Tang ZH
    BMJ Open; 2014 Jun; 4(6):e004744. PubMed ID: 24961714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin - a novel antibiotic against Gram-positive pathogens.
    LaPlante KL; Rybak MJ
    Expert Opin Pharmacother; 2004 Nov; 5(11):2321-31. PubMed ID: 15500379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daptomycin.
    Fenton C; Keating GM; Curran MP
    Drugs; 2004; 64(4):445-55; discussion 457-8. PubMed ID: 14969579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis.
    Durante-Mangoni E; Andini R; Parrella A; Mattucci I; Cavezza G; Senese A; Trojaniello C; Caprioli R; Diana MV; Utili R
    Int J Antimicrob Agents; 2016 Jul; 48(1):61-68. PubMed ID: 27259674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daptomycin.
    Heidary M; Khosravi AD; Khoshnood S; Nasiri MJ; Soleimani S; Goudarzi M
    J Antimicrob Chemother; 2018 Jan; 73(1):1-11. PubMed ID: 29059358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daptomycin: a review 4 years after first approval.
    Sauermann R; Rothenburger M; Graninger W; Joukhadar C
    Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
    Schrank GM; Wright SB; Branch-Elliman W; LaSalvia MT
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):947-954. PubMed ID: 29893658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
    Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA
    Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daptomycin in bone and joint infections: a review of the literature.
    Rice DA; Mendez-Vigo L
    Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.
    Kullar R; McClellan I; Geriak M; Sakoulas G
    Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient].
    Alvarez-Lerma F; Gracia-Arnillas MP
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():29-35. PubMed ID: 21477702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.
    Abdel-Rahman SM; Benziger DP; Jacobs RF; Jafri HS; Hong EF; Kearns GL
    Pediatr Infect Dis J; 2008 Apr; 27(4):330-4. PubMed ID: 18316988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.